RESEARCH ARTICLE

The In Vitro Antifungal Activity of Sudanese Medicinal Plants against Madurella mycetomatis, the Eumycetoma Major Causative Agent

Hassabelrasoul Elfadil1, Ahmed Fahal2*, Wendy Kloezen3, Elhadi M. Ahmed4, Wendy van de Sande3

1 Division of Pharmaceutical Microbiology, Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Gezira, Sudan, 2 The Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan, 3 Erasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands, 4 Department of Pharmacognosy, Faculty of Pharmacy, University of Gezira, Gezira, Sudan

* ahfahal@hotmail.com, ahfahal@uofk.edu

Abstract

Eumycetoma is a debilitating chronic inflammatory fungal infection that exists worldwide but it is endemic in many tropical and subtropical regions. The major causative organism is the fungus Madurella mycetomatis. The current treatment of eumycetoma is suboptimal and characterized by low cure rate and high recurrence rates. Hence, an alternative therapy is needed to address this. Here we determined the antifungal activity of seven Sudanese medicinal plant species against Madurella mycetomatis. Of these, only three species; Boswellia papyrifera, Acacia nubica and Nigella sativa, showed some antifungal activity against M. mycetomatis and were further studied. Crude methanol, hexane and defatted methanol extracts of these species were tested for their antifungal activity. B. papyrifera had the highest antifungal activity (MIC50 of 1 ug/ml) and it was further fractionated. The crude methanol and the soluble ethyl acetate fractions of B. papyrifera showed some antifungal activity. The Gas-Liquid-Chromatography hybrid Mass-Spectrophotometer analysis of these two fractions showed the existence of beta-amyrin, beta-amyrone, beta-Sitosterol and stigmatriene. Stigmatriene had the best antifungal activity, compared to other three phytoconstituents, with an MIC-50 of 32 μg/ml. Although the antifungal activity of the identified phytoconstituents was only limited, the antifungal activity of the complete extracts is more promising, indicating synergism. Furthermore these plant extracts are also known to have anti-inflammatory activity and can stimulate wound-healing; characteristics which might also be of great value in the development of novel therapeutic drugs for this chronic inflammatory disease. Therefore further exploration of these plant species in the treatment of mycetoma is encouraging.
Author Summary

This study was an attempt to discover new safe therapeutic modalities of natural origin for the treatment eumycetoma. The methanolic extracts of seven selected local plants were screened for their antifungal activity. All seven plant extracts were able to inhibit *Madurella mycetomatis* growth at a concentration of 50 μg/ml or less. Three plant species out of the seven managed to inhibit the growth of *Madurella mycetomatis* at a concentration as low as 781 μg/ml; these were: *Boswellia papyrifera*, *Acacia nubica* and *Nigella sativa*. Further analysis of *B. Papyrifera*, using Gas-Liquid-Chromatography hybrid Mass-Spectrophotometer (GC-MS); showed the occurrence of four phytoconstituents, triterpenoid in nature and these were Beta-amyrin, Beta-amyrone, Beta-Sitosterol and Stigmatriene. Stigmatriene was the best to show anti-mycetoma activity at an MIC equal to 32 μg/ml. This MIC is much higher than the MIC of the whole extract (8 μg/ml), indicating that other compounds or a combination of compounds has a better ability to inhibit *M. mycetomatis* growth. These results are promising and further detailed studies are highly recommended.

Introduction

Eumycetoma is a neglected tropical chronic subcutaneous inflammatory disease commonly caused by *Madurella mycetomatis*. It is characterised by a painless subcutaneous mass, multiple discharging sinuses and discharge that usually contains grains [1, 2]. The infection usually progresses to involve the skin, deep structures and ultimately the bone leading to massive deformities, distortions and disabilities [3, 4, 5].

Eumycetoma is reported worldwide but is endemic in tropical and subtropical regions, in what is known as the mycetoma belt and stretches between 15° South and 30° North of the equator [6]. Young active adults are mostly affected [7]. Mycetoma has several adverse effects on patients, communities and health authorities [8, 9].

The available eumycetoma treatment is a combination of massive surgical excisions and long term antifungal therapy [10, 11]. The therapeutic response to this regimen is suboptimal, characterized by low cure and high recurrence rates [12]. Currently ketoconazole and itraconazole are the antifungal drugs of choice. In Sudan, ketoconazole has been the drug of choice. Unfortunately, this drug can cause serious side effects such as hepatic toxicity, and is therefore in 2013 suspended for use by the US Food and Drug Administration and the European Medicines Agency. Furthermore, the drug appeared also expensive for people living in endemic areas, costing as much as a third of their monthly income [13,14]. Officially ketoconazole has now been replaced by itraconazole. Itraconazole is less toxic but unfortunately also appears to be less effective in mycetoma treatment. It creates a tough fibrous tissue around the mycetoma lesions which facilitate their surgical excision [14]. It is interesting to note in these lesions the organisms are commonly present and viable in culture which indicates that, these antifungal drugs are simply localizing the infection and not eradicating it [14]. This perhaps is quite astonishing as many *in vitro* studies showed that *M. mycetomatis* is inhibited in growth at low concentrations of these therapeutic agents [15, 16, 17, 18]. But this was explained by host factors and/or factors from the causative agent such as the grain melanin particularly DHN-melanin which proved to be responsible for this observation [19, 20].

Therefore there is a need for a better and more effective therapy for eumycetoma. An unexplored resource of novel therapeutic agents is the locally growing herbs which are often used in traditional medicine. A recently study conducted at the Mycetoma Research Centre, Sudan...
showed that, 42.4% of the studied population used herbal medicine for the treatment of eumycetoma at some stage of their illness with a complication rate of 29.3% [21]. Although such a large portion of the mycetoma patients use herbal medicine, there is relatively few information on the antifungal activity of these herbs. We therefore set out this study, to determine the antifungal activity of seven Sudanese plant species used in these local herbal treatments against *M. mycetomatis* in the hope to develop an alternative novel treatment for mycetoma in the future.

**Materials and Methods**

**Plant species used**

In this study seven Sudanese plants species were tested for antifungal activity against 13 independent clinical *M. mycetomatis* isolates. The parts tested were gum resin of *Boswellia papyrifera* of the family Burseraceae, root bark of *Acacia nubica* of the Mimosaceae family, seeds and fruits of *Nigella sativa* of the family Renunculaceae, flower buds of *Eugenia caryophyllus* of the family Myrtaceae, rhizome of *Zingiber officinalis* of the family Zingiberaceae, stem peel of *Cinnamomum verum* of the family Lauraceae and fruits of *Piper nigrum* of the family Piperaceae.

**Preparations of the plant extracts**

The plant extracts were prepared from dried coarsely powdered samples macerated separately in conical flasks with methanol over seven days at room temperature. Following filtration, crude methanolic extracts were dried under vacuum using a rotatory evaporator at 60°C. The extracts were dissolved separately in 70% alcohol and subjected to liquid-liquid partitioning using hexane to obtain three products: a crude methanol extract, a hexane fraction and a defatted methanol fraction as described previously. [22, 23, 24]

**Identification of potential antifungal components in the crude extracts of *Boswellia papyrifera***

To determine which components in these extracts were responsible for the antifungal activity of *Boswellia papyrifera*, methanol extracts were fractionated using a separating funnel successively with hexane and ethyl acetate to produce four fractions: an exhausted methanol fraction, a hexane fraction, a crude methanol extract and an ethyl acetate fraction. The fraction in which the antifungal activity was detected was further characterized by Gas liquid Chromatography hybrid Mass spectrophotometry (GC-MS) analysis.

For this extracts were dissolved in ethyl acetate, and one μl injections were made in split mode at injection temperature 280°C. Initial temperature was 80°C, then increased at 10°C/min; compounds were identified by comparison of their mass spectra with those from the NIST’98 mass spectral database. The identified triterpenoid phytoconstituents were Beta-amyrin, Beta-amyrone, Beta-sitosterol and Stigmatriene. To test the antifungal activities of these phytoconstituents, the pure compounds were purchased by Sigma.

**Determining the *in vitro* activities of the different extracts and compounds against *M. mycetomatis***

The broth microdilution method was used to determine the crude methanol extract, hexane fraction, defatted methanol fraction, crude methanol fraction, exhausted soluble methanol fraction, soluble hexane fraction, soluble ethyl acetate fraction, Beta-amyrin, Beta-amyrone, Beta-sitosterol and Stigmatriene antifungal activity against clinical *M. mycetomatis* isolates.
Each of the *M. mycetomatis* isolates was identified to the species level by sequencing the ITS region [15–18]. The procedure started with the culturing of *M. mycetomatis* for 10 days at 37° in RPMI-1640 medium supplemented with L-glutamine (0.3 g/L) and 6 ml MOPS of 0.165 M. The resulting mycelia were harvested by 5 minutes centrifugation at 2158 g and washed with normal saline. The mycelia were homogenized by sonication for 20 seconds at 28 micron, using a sonicator (Mesonix-CEMODEL3510E-MT-Mexico S/Nqpo40517794). The final inoculum was prepared by adjusting the homogenized fungal suspension to obtain an optical transmission of 70% at 660 nm. Of this suspension 100 microliters were transferred into a microtitration plate. To each well 2 μl of a two-fold dilution of each extract in DMSO was added. The microtitration plate was incubated for 7 days at 37°C before the endpoints were read. The MIC was determined to be the first well in which no growth was visible. Biological assays were compared to negative, positive; inoculum and solvent controls. As a comparator agent, ketoconazole was applied in all plates. All assays were performed in triplicate. To facilitate the endpoint reading, XTT was added after incubation as described elsewhere [22].

**Results**

The extracts from *Boswellia papyrifera* appear to have the most potent antifungal activity against *M. mycetomatis*

In order to determine if seven of the locally used medicinal plants have any antifungal activity against *M. mycetomatis*, crude methanol extracts of *E. caryophillus, C. verum, P. nigrum, Z. officinalis, A. nubica, N. sativa* and *B. papyrifera* were prepared (Table 1). All the studied methanol extracts were able to inhibit *M. mycetomatis* growth at a concentration of 50 μg/ml. Three of these extracts had a more potent antifungal activity and these were *A. nubica, N. sativa* and *B. papyrifera*. They inhibited *M. mycetomatis* growth at a concentration as low as 1 μg/ml (Table 1). Hence, these three plant species were selected for further study. Crude methanol extracts, hexane extracts and the defatted methanol extracts were prepared from these plant species and their antifungal activities were determined for the clinical *M. mycetomatis* isolates. Low MICs were found for all three extracts, with MIC-50s ranging from 1 μg/ml to 4 μg/ml (Table 1).

The most potent antifungal activity was documented in the crude methanol extracts of *B. papyrifera* (Table 1). The crude methanol fraction of *B. papyrifera* was further fractionated into four different fractions: a crude methanol fraction, an exhausted soluble methanol fraction, a soluble hexane fraction and a soluble ethyl acetate fraction to determine in which of these fractions the antifungal activity was present. The *M. mycetomatis* growth was inhibited only by the crude methanol fraction and the soluble ethyl acetate fraction, (Table 1).

To determine the exact nature of the antifungal compounds, GC-MS analyses were performed on the crude methanol extract and the soluble ethyl acetate fractions. It appeared that in both extracts high amounts of tetracyclic and pentacyclic triterpenoid compounds were present. These compounds were identified as: Beta-amyrin, Beta-amyrone, Beta-sitosterol and Stigmatriene based on the comparison of their retention times and masses with those from the NIST’98 mass spectral database (Table 2). Strikingly, only Beta-amyrone and Stigmatriene were present in both extracts in relatively high concentrations.

Since in the active fractions of the *B. papyrifera* extracts; high concentrations of Beta-amyrin, Beta amyrone, Beta-sitosterol and Stigmatriene were found, it was our plan to determine if any of these phytoconstituents can exhibit antifungal activity against *M. mycetomatis*. Findings revealed that, Beta-amyrin, beta-amyrone and beta-sitosterol only had limited activity against *M. mycetomatis* (Table 3). Only four isolates were inhibited by lower concentrations of beta-amyrin and beta-amyrone and only two for beta-sitosterol. The other isolates were not
inhibited by these compounds at the highest concentration tested. For stigmatriene most isolates were inhibited at lower concentrations and only four isolates were not inhibited at all. But even for stigmatriene the overall MICs obtained were relatively high, compared to the whole extract.

Discussion

In many centers extensive eumycetoma lesions are still treated with a combination of massive surgical excisions (or amputation) and prolonged antifungal therapy [10,11]. These treatment modalities are based on personal clinical experience and a few case reports rather than controlled clinical trials [10]. The treatment outcome is appalling and dreadful characterized by low cure rate, high recurrence and complications rates [12]. Eumycetoma patients characteristically have high drug incompliance and follow-up dropout rates due to the gross patients' dissatisfaction with the current treatment [12]. Hence, there is a pressing need for novel therapeutic approaches.

Table 1. In vitro antifungal activities of several extracts of seven locally plant species against 13 *M. mycetomatis* isolates.

| Plant species                  | MIC 50\(^1\) (range) | Hexane extract | Defatted methanol extract | Crude methanol fraction | Exhausted soluble methanol fraction | Soluble hexane fraction | Soluble ethyl acetate fraction |
|--------------------------------|-----------------------|----------------|---------------------------|-------------------------|-------------------------------------|------------------------|-------------------------------|
| *Eugenia caryophillus*         | 50 (ND\(^2\))         | ND (ND)        | ND (ND)                   | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Cinnamum verum*               | 25 (ND)               | ND (ND)        | ND (ND)                   | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Piper nigrum*                 | 25 (ND)               | ND (ND)        | ND (ND)                   | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Zingiber officinalis*         | 12.5 (ND)             | ND (ND)        | ND (ND)                   | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Acacia rubica*                | 1 (0.5–128)           | 2 (0.25–128)   | 4 (0.5–128)               | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Nigella sativa*               | 1 (0.5–128)           | 2 (0.25–128)   | 4 (0.25–128)              | ND (ND)                 | ND (ND)                             | ND (ND)                | ND (ND)                       |
| *Boswellia papyrifera*         | 1 (0.5–128)           | 1 (0.25–128)   | 2 (0.25–128)              | 8 (8)                   | 128 (128)                           | 128 (128)              | 8 (8)                         |
| Ketoconazole                   | 0.125 (0.03–0.25)     |                |                           |                         |                                     |                        |                               |

\(^1\)Minimal inhibitory concentrations (MIC) at which at least 50% of the *M. mycetomatis* isolates was inhibited (MIC\(^50\)).

\(^2\)ND: not done.

doi:10.1371/journal.pntd.0003488.t001

Table 2. GC-MS analysis presenting triterpenes identified by GC/MS in *Boswellia papyrifera* extracts.

| Fraction             | Retention time | % area | Base peak | Molecular weight | Identification of compound |
|----------------------|----------------|--------|-----------|-------------------|----------------------------|
| Crude methanol       | 20.614         | 18.24  | 218       | 424               | beta-amyronone             |
| 20.757               | 0.48           | 392    | 410       |                   | Stigmatriene               |
| 22.09                | 20.17          | 218    | 426       |                   | beta-amyrin                |
| Soluble ethyl acetate| 20.614         | 12.46  | 218       | 424               | beta-amyronone             |
| 20.757               | 72.41          | 392    | 410       |                   | Stigmatriene               |
| 21.752               | 2.53           | 129    | 486       |                   | beta-sitosterol            |

doi:10.1371/journal.pntd.0003488.t002
Although, plants have been traditionally used as local remedies against various infectious diseases, their activity against mycetoma causative agents have been hardly studied. Only one report appeared to literature which studied the in vitro activity of plant extracts such as artemisinin and tea tree oil on *M. mycetomatis*. In that study it was demonstrated that that artemisinin was not active against *M. mycetomatis*, but tea tree oil did inhibit its growth at concentrations below 0.25% (v/v), which was comparable to other fungal species [18,25]. Tea tree oil is a product not available in the Sudan and hence we tested other local plant species with reported antifungal activities.

Seven locally accessible medicinal plant species were selected and tested for activity against eumycetoma. The study demonstrated variable antifungal activity against *M. mycetomatis*, but the plants *Boswellia papyrifera*, *Acacia nubica* and *Nigella sativa* appeared to be the most potent ones. The fact that, extracts of *B. papyrifera* showed antifungal activity against *M. mycetomatis* is not surprising since the antibacterial and antifungal activities of *B. carterii*, *B. neglecta*, *B. sacra*, *B. thurifera*, *B. frereana*, *B. papyrifera*, *B. socrotrana* and *B. papyrifera* are widely reported [26][27]. Furthermore, *Boswellia* essential oils were not only able to inhibit the fungal growth, they were also able to inhibit germ tube formation in *C. albicans* [26–28] and to prevent Candida *albicans* biofilm formation [26–28–29–30], both important for pathogenicity. Especially the latter feature could be important in mycetoma too. The *Candida* biofilm is composed of *Candida* cells immobilized in matrix, known to consist mainly of carbohydrates and small amounts of protein, hexosamine, phosphorus and uronic acid [29–30]. Likewise, the *M. mycetomatis* grain also consists of fungal cells entrapped in a matrix like material called cement [28–29–30]. The composition of the cement differs from that of the *Candida* biofilm in that it is carbohydrate poor, and rich in fat and proteins [29–30], but like the *Candida* biofilm it is highly resistant against antifungal agents. Therefore any compound able to inhibit *Candida* biofilm formation or even to disrupt this biofilm might be able to do the same with the cement material of the *M. mycetomatis* grain.

Next to the reported *B. papyrifera* antifungal activities, *Boswellia* species also have known to possess bioactive molecules which are active in inflammatory and malignant diseases and in wound healing [31–32]. The compounds responsible for this anti-inflammatory reaction are thought to be boswellic acids and quercetin [32–34]. From in vitro studies and animal models it was learned that, boswellic acids inhibit the synthesis of pro-inflammatory enzymes, 5-lipoxigenase and leukotriene B and thereby prevent bronchoconstriction, chemotaxis, and decrease vascular permeability [32–33]. Furthermore, the anti-inflammatory activity of mixture of boswellic acids produced a 25–46% inhibition of paw oedema in rats and mice [35], which could be important in the mycetoma pathology since large swellings are also present in this disease. Furthermore, since a large inflammation zone is present surrounding the grain (33), any essential oil which also has anti-inflammatory properties will have some effect on the pathogenesis of this disease.

### Table 3. In vitro antifungal activities identified of triterpenoidal compounds from the *B. papyrifera* extracts against 12 *M. mycetomatis* isolates.

| Compound              | MIC50 (range) in μg/ml |
|-----------------------|------------------------|
| beta-amyrin           | >256 (0.5->256)        |
| beta-amyrone          | >128 (0.25 -> >128)   |
| beta-sitosterol       | >128 (0.125 -> >128)  |
| stigmatriene 32       | 32 (0.125->128)        |

doi:10.1371/journal.pntd.0003488.t003
Furthermore, although the *Boswellia papyrifera* extracts in overall appear to be effective and safe to administer [37–38–39–40], identification of the active phytoconstituents is still mandatory. This is important to decrease the probabilities of expected adverse effects and to dramatically increase the prospective extract efficacy when the isolated compounds are used as medication.

The study showed that, the overall the purified stigmatriene MICs were much less than for the crude extracts. This indicates that either stigmatriene is not the only antifungal compound present or that the different components present in the crude extracts might act synergistically. Indeed, in other studies several other compounds were found to be the active ingredient of *Boswellia* resins [26,27,28]. Based on these observations, more studies are needed on the antifungal mechanism of these extracts before they can be developed as potential new antifungal agents for the treatment of eumycetoma.

In conclusion, the present study showed that, *B. papyrifera*, *A. nubica* and *N. sativa* have some *in vitro* antifungal activity against *M. mycetomatis*, and the most potent were the *B. papyrifera* extracts. Although the antifungal activity of the identified compounds in these extracts was only limited, and the antifungal activity of the complete extracts was more promising. Furthermore these plant extracts are also known to have anti-inflammatory activity and stimulate wound-healing and that can be helpful in managing patients with mycetoma.

**Author Contributions**

Conceived and designed the experiments: HE AF WK EMA WvdS. Performed the experiments: HE AF WK EMA WvdS. Analyzed the data: HE AF WK EMA WvdS. Contributed reagents/materials/analysis tools: HE AF WK EMA WvdS. Wrote the paper: HE AF WK EMA WvdS.

**References**

1. Fahal AH. (2013) Mycetoma in Williams, Bulstrode, O’Connell, Bailey and Love’s Short Practice of Surgery 26E: 26th Edition, Oxford University Press, pp 64–68.
2. Fahal AH. (2011) Mycetoma in Richard, Guerrant, Walker, Peter, Tropical Infectious Diseases: Principles, Pathogens and Practice. Third edition, Elsevier Publisher, chapter 83, pp. 565–568. doi: 10.1007/s13197-011-0525-7 PMID: 24587533
3. Fahal AH. (2011) Mycetoma. Review article, Khartoum Med J. 4(1): 514–523.
4. Fahal AH, Hassan MA (1992) Mycetoma. Br J Surg 79(11): 1138–1141. PMID: 1467883
5. Fahal AH (2004) Mycetoma thorn on the flesh. Review article. Trans R Soc Trop Med Hyg 98(1):3–11. PMID: 14702833
6. Fahal AH, van de Sandy WW (2012) The Epidemiology of mycetoma. Curr Fungal Infect Rep 6 (4): 320–326.
7. Van Belkum A, Fahal A, van de Sande WW (2013) Mycetoma caused by Madurella mycetomatis: a completely neglected medico-social dilemma. Adv Exp Med Biol 764:179–189. PMID: 23654067
8. Ahmed AA, van de Sande WW, Fahal AH, Bakker-Woudenberg I, Verbrugh H, et al. (2007) Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis. 20(2):146–51. PMID: 17496572
9. Ahmed AO, van Leeuwen W, Fahal A, van de Sande WW, Verbrugh H, et al. (2004) Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 4(9):566–74 PMID: 15336224
10. Fahal AH, Elkhawad AO. (2013) Treating Mycetoma: Guidelines for Best Practice. Expert Rev Dermatol 8(3): 301–307.
11. Fahal AH. (2010) Management of mycetoma. Expert Rev Dermatol 5(1), 87–93.
12. Zein HAM, Fahal AH, Mahgoub ES, EL Hassan T, Abdel Rahman ME. (2012) The Predictors of Cure, Amputation & Follow-up dropout among Mycetoma Patients as seen at The Mycetoma Research Centre, University of Khartoum. Trans R Soc Trop Med Hyg. 106(11):639–44. doi: 10.1016/j.trstmh.2012.07.009 PMID: 22854685
13. Mahgoub ES, Gumaa SA. (1984) Ketoconazole in the treatment of eumycetoma due to Madurella mycetomi. Trans R Soc Trop Med Hyg 78:376–79. PMID: 6087513

14. Fahal AH, Rahman IA, El-Hassan AM, EL Rahman ME, Zijlstra EE. (2011) The efficacy of itraconazole in the treatment of patients with eumycetoma due to Madurella mycetoma. Trans R Soc Trop Med Hyg. 105 (3):127–32. doi: 10.1016/j.trstmh.2010.11.008 PMID: 21247608

15. Wendy Kloezen, Meis Jacques F., Ilse Curfs-Breuker Ahmed Fahal, van de Sande Wendy WJ. (2012) In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrobial Agents Chemother. 56(11):6054–6. doi: 10.1128/AAC.01170-12 PMID: 22964246

16. Ahmed AO, van de Sande WW, van Vianen W, van Belkum A, Fahal AH, et al. (2004). In vitro susceptibility of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrobial Agents Chemother 48(7):2742–6. PMID: 15215141

17. van Belkum A, Fahal HA, Wendy van de Sande WW. (2011) In Vitro Susceptibility of Madurella Mycetomatis to Posaconazole and Terbinafine. Antimicrob Agents Chemother. 55(4):1771–3. doi: 10.1128/AAC.01045-10 PMID: 21263050

18. van de Sande WW, Fahal AH, Riley TV, Verbrugh H, van Belkum A. (2007). In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin. J Antimicrob Chemother. 59(3):553–5. PMID: 17324961

19. van de Sande WW, de Kat J, Coppens J, Ahmed AO, Fahal A, et al. (2007) Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect. 9: 1114–1123. PMID: 17644456

20. Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW. (2013) A histopathological exploration of the Madurella mycetomatis grain. PLoS One. (8(3):e57774. Epub 2013 Mar 6. doi: 10.1371/journal.pone.0057774 PMID: 23483927

21. Ezaldeen EA, Fahal AH, Osman A. (2013) Mycetoma Herbal Treatment: The Mycetoma Research Centre, Sudan Experience. PLoS Negl Trop Dis 7(8):e2400. doi: 10.1371/journal.pntd.0002400 PMID: 23991244

22. National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa (2002).

23. Raaman N. (2006) Phytochemical Techniques. New India Publishing Agency, Chapter six, pp. 40–67. doi: 10.1016/j.nepr.2005.06.003 PMID: 19040854

24. Banso A. (2009) Phytochemical and antibacterial investigation of bark extract of Acacia nubica. J. Med. Plants Res 3 (2):082–085.

25. Hammer KA, Carson CF, Riley TV. (2003) Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol. 95: 853–60. PMID: 12969301

26. Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. (2007) Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Annali di Chimica, 9(97), 837–844. PMID: 17970299

27. Abdoul-latif FM, Louis-Clément O, Imael HN, Dicko MH. (2012) Antimicrobial activities of essential oil and methanol extract of Boswellia sacra Flueck. and Boswellia papyrifera (Del.) Hochst from Djibouti. Int J Mment, Mod Sc Technol 1(1): 1

28. Wesenberg-Ward KE, Tyler BJ, Sears JT. (2005) Adhesion and biofilm formation of Candida albicans on native and Pluronic-treated polystyrene. Biofilms, 1(2), Biofilms 63–844. PMID:17970299

29. Schillaci D, Arizza V, Dayton T, Camarda L, Di Stefano V. (2008) In vitro anti-biofilm activity of Boswellia spp. oleogum resin essential oils, Letters in Applied Microbiology 5(47): 433–438. doi: 10.1111/j.1472-765X.2008.02469.x PMID: 19146534

30. Al-Fattani MA, Douglas LJ (2006) Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 55(8):999–1008.

31. Hostanska K, Daum G, Saller R (2002) Cytostatic and apoptosis-inducing activity of boswellic acids to-ward malignant cell lines in vitro. Anticancer Res 22:2853–2862. PMID: 12530009

32. Ammon HP, Safayi H, Mack T, Sabieraj J. (1993) Mechanism of anti-inflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 38 (2–3): 113 –9. PMID: 8099636

33. Fahal AH, El Toum E, El Hassan AM, Mahgoub ES, Gumaa SA. (1995) The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol 33(5): 15–17. PMID: 8544084

34. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, et al. (2006) Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol 290 (6):1131–7. doi: 10.1152/ajppl.00562
35. Sharma A, Bhatia S, Kharya MD, Gajbhiye V, Ganesh N, et al. (2010) Anti-inflammatory and analgesic activity of different fractions of Boswellia serrata. Int J Phytomed 1(2): 94–99.

36. Liu M, Chen P, Büchele B, Dong S, Huang D, et al. (2013) A boswellic acid-containing extract attenuates hepatic granuloma in C57BL/6 mice infected with Schistosoma japonicum. Parasitol Res 112(3):1105–11. doi: 10.1007/s00436-012 PMID: 23271565

37. Devi PR, Adilaxmamma K, Rao GS, Srilatha Ch, Raj MA (2012) Safety Evaluation of Alcoholic Extract of Boswellia ovalifoliata Stem-bark in Rats. Toxicol Int 19(2):115–20. doi: 10.4103/0971-6580.97198 PMID: 22778507

38. Ahmed M, Al-Daghri N, Alokail MS, Hussain T (2013) Potential changes in rat spermatogenesis and sperm parameters after inhalation of Boswellia papyrfera and Boswellia carterii incense. Int J Environ Res Public Health 10(3):830. doi: 10.3390/ijerph10030830 PMID: 23449005

39. Mahmoudi A, Hosseini-Sharifabad A, Monsef-Esfahani HR, Yazdinejad AR, Khanavi M, et al. (2011) Evaluation of systemic administration of Boswellia papyrfera extracts on spatial memory retention in male rats. J Nat Med 65(3–4):519–25. doi: 10.1007/s11418-011-0523-0 PMID: 21479861

40. Singh P, Chacko KM, Aggarwal ML, Bhat B, Khandal RK, et al. (2012) A-90 Day Gavage Safety Assessment of Boswellia serrata in Rats. Toxicol Int 19(3):273–8. doi: 10.4103/0971-6580.103668 PMID: 23293466